Contributions
Abstract: PB1889
Type: Publication Only
Background
Lipegfilgrastim (Lonquex®) is a long-acting fixed-dose glycopegylated granulocyte colony-stimulating factor administered once per chemotherapy cycle. It has been available in Europe since 2013. It was proven to be non-inferior with regard to duration of severe neutropenia compared with pegfilgrastim in breast cancer patients. However, data in patients with hematological malignancies are limited.
Aims
We aimed to evaluate the effectiveness of lipegfilgrastim in the cycle following the first lipegfilgrastim-supported treatment cycle in lymphoma patients.
Methods
This is a prospective observational cohort study. Patients with different tumor types treated with cytotoxic chemotherapy (CT) who received lipegfilgrastim in primary prophylaxis (PP) or secondary prophylaxis (SP) are being included in this study. CT dose modifications and neutropenia-related events are recorded and analyzed. Evaluation of effectiveness in the cycle following the first lipegfilgrastim-supported CT cycle in a lymphoma subpopulation is presented here.
Results
At the time of the interim analysis (December 2016), 249 patients diagnosed with lymphoma have been included. Mean age ± standard deviation of lymphoma patients was 61.6 ± 15.6 years and 56.6% were male. For the majority of patients (81.1%), intended use of lipegfilgrastim was in PP. Exposure to lipegfilgrastim has been documented for 228 patients with an average of 4.76 cycles per patient. Data on CT dose modifications and neutropenic events following the first lipegfilgrastim-supported cycle were available for 144 and 167 patients, respectively. CT dose was never omitted. CT dose delays were observed in 8.0% (PP) and 18.8% (SP) of patients and CT dose reductions in 4.5% (PP) and 12.5% (SP) of patients. In the first lipegfilgrastim-supported cycle, febrile neutropenia was recorded in 4.5% (PP) and 3.0% (SP) of patients; severe neutropenia was recorded in 7.5% (PP) and 9.1% (SP) of patients. Throughout the treatment, 22 (9.6%) patients exposed to lipegfilgrastim reported at least 1 adverse drug reaction (ADR). The most common ADRs were myalgia and musculoskeletal pain. Serious ADRs were reported by 11 (4.8%) patients.
Conclusion
Lipegfilgrastim is effective and well tolerated in the real-world setting in lymphoma patients, administered either in PP or SP. The results suggest that lipegfilgrastim administered in PP might give better outcomes in terms of dose delays and dose reductions than when administered in SP.
Session topic: 29. Infectious diseases, supportive care
Abstract: PB1889
Type: Publication Only
Background
Lipegfilgrastim (Lonquex®) is a long-acting fixed-dose glycopegylated granulocyte colony-stimulating factor administered once per chemotherapy cycle. It has been available in Europe since 2013. It was proven to be non-inferior with regard to duration of severe neutropenia compared with pegfilgrastim in breast cancer patients. However, data in patients with hematological malignancies are limited.
Aims
We aimed to evaluate the effectiveness of lipegfilgrastim in the cycle following the first lipegfilgrastim-supported treatment cycle in lymphoma patients.
Methods
This is a prospective observational cohort study. Patients with different tumor types treated with cytotoxic chemotherapy (CT) who received lipegfilgrastim in primary prophylaxis (PP) or secondary prophylaxis (SP) are being included in this study. CT dose modifications and neutropenia-related events are recorded and analyzed. Evaluation of effectiveness in the cycle following the first lipegfilgrastim-supported CT cycle in a lymphoma subpopulation is presented here.
Results
At the time of the interim analysis (December 2016), 249 patients diagnosed with lymphoma have been included. Mean age ± standard deviation of lymphoma patients was 61.6 ± 15.6 years and 56.6% were male. For the majority of patients (81.1%), intended use of lipegfilgrastim was in PP. Exposure to lipegfilgrastim has been documented for 228 patients with an average of 4.76 cycles per patient. Data on CT dose modifications and neutropenic events following the first lipegfilgrastim-supported cycle were available for 144 and 167 patients, respectively. CT dose was never omitted. CT dose delays were observed in 8.0% (PP) and 18.8% (SP) of patients and CT dose reductions in 4.5% (PP) and 12.5% (SP) of patients. In the first lipegfilgrastim-supported cycle, febrile neutropenia was recorded in 4.5% (PP) and 3.0% (SP) of patients; severe neutropenia was recorded in 7.5% (PP) and 9.1% (SP) of patients. Throughout the treatment, 22 (9.6%) patients exposed to lipegfilgrastim reported at least 1 adverse drug reaction (ADR). The most common ADRs were myalgia and musculoskeletal pain. Serious ADRs were reported by 11 (4.8%) patients.
Conclusion
Lipegfilgrastim is effective and well tolerated in the real-world setting in lymphoma patients, administered either in PP or SP. The results suggest that lipegfilgrastim administered in PP might give better outcomes in terms of dose delays and dose reductions than when administered in SP.
Session topic: 29. Infectious diseases, supportive care